about
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).Current therapy of myelodysplastic syndromesRibosomopathies: mechanisms of disease.Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.Review of therapeutic options and the management of patients with myelodysplastic syndromes.Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomesMyelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.
P2860
Q33424228-DF50419B-3217-4CF0-95D1-6C9DB6AC2854Q34013796-E9FCB405-8E10-42DB-B569-5AD9B43052E0Q34454066-F6B2AB61-00CC-4829-B88F-CA6BCF047E09Q37074311-45F09544-DF63-4E08-A86F-5A20B07F750FQ38095121-50028117-4C87-499D-BA0C-44E05FB08AB5Q38135713-13FA8648-60E2-49F3-903A-C4BC4788902AQ38195796-9137E8EB-D176-4EAB-9EE8-5E4F9BED8765Q38687894-1EA26829-D936-402C-AB4A-F8175F35C71E
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biology and treatment of the 5q- syndrome.
@en
Biology and treatment of the 5q- syndrome.
@nl
type
label
Biology and treatment of the 5q- syndrome.
@en
Biology and treatment of the 5q- syndrome.
@nl
prefLabel
Biology and treatment of the 5q- syndrome.
@en
Biology and treatment of the 5q- syndrome.
@nl
P2860
P356
P1476
Biology and treatment of the 5q- syndrome
@en
P2093
Eric Padron
Rami Komrokji
P2860
P356
10.1586/EHM.11.2
P50
P577
2011-02-01T00:00:00Z